Eliem Therapeutics Inc
NASDAQ:ELYM

Watchlist Manager
Eliem Therapeutics Inc Logo
Eliem Therapeutics Inc
NASDAQ:ELYM
Watchlist
Price: 3.09 USD -1.9% Market Closed
Market Cap: 207.7m USD
Have any thoughts about
Eliem Therapeutics Inc?
Write Note

Eliem Therapeutics Inc
Net Change in Cash

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

Eliem Therapeutics Inc
Net Change in Cash Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Net Change in Cash CAGR 3Y CAGR 5Y CAGR 10Y
Eliem Therapeutics Inc
NASDAQ:ELYM
Net Change in Cash
$49.5m
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Abbvie Inc
NYSE:ABBV
Net Change in Cash
-$6B
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
-17%
Gilead Sciences Inc
NASDAQ:GILD
Net Change in Cash
-$669m
CAGR 3-Years
57%
CAGR 5-Years
33%
CAGR 10-Years
N/A
Amgen Inc
NASDAQ:AMGN
Net Change in Cash
-$25.7B
CAGR 3-Years
N/A
CAGR 5-Years
-116%
CAGR 10-Years
-19%
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
Net Change in Cash
-$5.9B
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
Net Change in Cash
-$148.4m
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
No Stocks Found

Eliem Therapeutics Inc
Glance View

Market Cap
206.4m USD
Industry
Biotechnology

Eliem Therapeutics, Inc. operates as a clinical-stage biotechnology company. The company is headquartered in Redmond, Washington and currently employs 19 full-time employees. The company went IPO on 2021-08-10. The firm focuses on developing novel therapies for neuronal excitability disorders that addresses unmet needs in chronic pain, neuropsychiatry, epilepsy, and other disorders of the perishable and central nervous system. The firm offers two lead clinical-stage candidates: ETX-810 and ETX-155. ETX-810 is a palmitoylethanolamide (PEA) prodrug developed for the treatment of diabetic peripheral neuropathic pain (DPNP) and pain associated with lumbosacral radiculopathy (LSRP). ETX-810 is being evaluated in two Phase II a clinical trial. ETX-155 is a neurosteroid gamma-aminobutyric acid type A (GABAA) receptor positive allosteric modulator (PAM) developed for major depressive disorder (MDD), perimenopausal depression (PMD) and focal onset seizures (FOS). The firm provides two programs in addition to its clinical candidates, namely Kv7.2/3 program and anxiolytic.

ELYM Intrinsic Value
1.59 USD
Overvaluation 49%
Intrinsic Value
Price

See Also

What is Eliem Therapeutics Inc's Net Change in Cash?
Net Change in Cash
49.5m USD

Based on the financial report for Dec 31, 2023, Eliem Therapeutics Inc's Net Change in Cash amounts to 49.5m USD.

Back to Top